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Abstract 
Transglutaminase 2 (TG2) is a multifunctional member of an enzyme family: it modifies glutamine residues by cross-linking 
proteins and incorporating primary amines into them, has protein disulphide isomerase and protein kinase activities, mediates 
trans-membrane signal transduction and interactions between cell surface proteins and the extracellular matrix. These unusual 
multiple roles encoded into one polypeptide chain suggest that genomic variations in the TGM2 gene should be limited. Indeed, 
the available information in databases shows that unlike in the case of most other transglutaminases there are no common single 
nucleotide polymorphisms in exons of human TGM2. We collected data on and produced some of the rare genetic variants of 
TGM2 by site directed mutagenesis and found that some were less stable than the most abundant (wild type) enzyme variant and 
the majority had deficient transamidating activity. Further studies are required to clarify the pathologic significance of these rare 
TGM2 alleles in the human population. 
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Introduction 
Transglutaminase research started more than five decades ago when Waelsch and co-workers observed a Ca
2+
-dependent activity 
in liver extracts incorporating primary amines into proteins (Sarkar et al. 1957; Mycek et al. 1959). In the sixties there were two 
important developments. First, the chemical nature of the cross-link formed in fibrin (Laki and Lorand, Science 1948) by blood 
coagulation factor XIIIa, a plasma transglutaminase (Loewy 1968), was revealed (Pisano et al. 1968; Matatic and Loewy 1968; 
Lorand et al. 1968). Second, the purification of tissue transglutaminase (later named transglutaminase 2; TG2) from guinea pig 
liver could be achieved (Folk and Cole 1966) in the NIH laboratory of Jack Folk, opening the way to the characterization of its 
enzymatic properties in details; the findings were summarized in the early seventies by Folk and Chung providing a basis of 
further developments in the field (Folk and Chung 1973). 
In the pioneering TG2 experiments, and even later works with human transglutaminase 2 obtained from endothelial, red 
blood or other types of cells, it was assumed that the studied enzyme preparation represented a reproducibly obtainable 
homogenous protein population with the same amino acid sequence. After the completion of the human genome project and the 
availability of the HapMap (Thorisson et al. 2005) and other databases, it became evident that the vast majority of our proteins are 
polymorphic due mainly - but not exclusively - to single nucleotide polymorphism (SNP). The data presented by the 1000 
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Genomes Project (1000 Genomes Project Consortium 2010) have established the normal de novo mutation rate to be ~1.1 × 10-8 
bp for a human haploid genome. Therefore, differences amounting to several million SNPs exist between the genome of any two 
individuals, of which tens of thousands are in protein coding exons. As a consequence, proteins encoded by the two parental 
chromosomes may differ significantly due to their individual polymorphism. The inherited rare genetic variations (most often 
SNPs) in the Mendelian disorder genes result in defective proteins leading to severe pathologic conditions in either their homo- or 
heterozygous forms. Examples in the transglutaminase protein family include the life threatening bleeding syndrome as a 
consequence of any of the more than 70 reported disease causing mutations of FXIIIa (Duckert et al. 1960; Karimi et al. 2009) and 
lamellar ichtiosis in cases of TGM1 mutations (Huber et al. 1995). No such genetic mutation of TG2 has been reported so far. 
Most of our genes also have common variants and the significance of these SNPs have been the subject of a large number of 
genome wide association studies to reveal their contribution to or role in multi-factorial complex diseases. For example, the 
Val34Leu SNP of FXIIIa (25% prevalence in whites) provides a moderate protection against coronary artery disease (Muszbek et 
al. 2010). Regarding TG2 systemic analysis of its polymorphisms has not been carried out yet. 
In this paper, based on population genetic data (NCBI, Uniprot, HapMap, Ensemble, 1000 Genom datadases, Complete 
Genomics), we present the sequence of the most abundant (wild type) TG2 protein sequence and provide an overview of its so far 
found SNPs. Several of the TGM2 mutant forms have been produced and tested in biochemical assays. We compare the 
prevalence of TGM2 SNPs to those in other members of the transglutaminase family and discuss the possible reasons of the 
surprisingly low frequency of genetic variations in the protein coding sequence of TGM2. 
 
Materials and methods 
 
Databases and bioinformatic background 
We used the standard websites of the NCBI, UniProt, HapMap, Ensembl (Galperin and Cochrane 2011), 1000 Genome and 
Complete Genomics databases for browsing the data and retrieving the relevant sequences. The 1000 Genomes data frequencies 
were extracted from the VCF file using the vcftools program (Danecek et al. 2011). For analyzing the Complete Genomics data 
(Drmanac et al. 2010) the REFSEQ gene variation tables of the high coverage sequencing of 46 individuals (diversity panel) were 
downloaded. The relevant diversity data were extracted from these tables using BASH shell scripts. 
 
Transglutaminase enzyme preparations 
The cloned (Gentile et al. 1991) and variant recombinant human TG2s were expressed in N-terminally (His)6-tagged form and 
were purified by Ni-NTA affinity chromatography as described previously (Kiraly et al. 2009). TG2 variants were constructed 
based on the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) and were checked by restriction 
analysis and DNA sequencing (ABI PRISM). The protein concentration was determined using the Bradford method (Bio-Rad, 
München, Germany). The purity of proteins was checked by Coomassie BB staining of SDS-poliacrylamide gels and by Western 
blots. 
 
Antibody binding assays 
Antigenicity and functional purity of TG2 proteins were determined by direct ELISA using G92 (G92.1.2; Trejo-Skalli et al. 
1995; 1:3000), CUB7402 (NeoMarkers, Fremont, CA, USA; 1:2000), TG100 (NeoMarkers; 1:2000) mouse monoclonal anti-TG2 
and human coeliac antibodies as described earlier (Kiraly et al. 2009). The wells were coated with 0.5 μg protein for 1 hour at 4oC. 
After washing, the antibody solutions were incubated in the wells for 1 hour at room temperature. The bound antibodies were 
detected using anti-mouse IgG/HRP or anti-human IgA IgG/HRP antibodies and TMB substrate. 
 
Fibronectin binding 
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The fibronectin binding property of the variants was tested using a direct ELISA assay. The wells were coated with 0.3 μg 
fibronectin in carbonate buffer pH 9.6 at 4
o
C for 1 hour. After washing, 0.5 μg TG2 variant was incubated in the wells for 1 hour 
at room temperature. The bound TG2 variants were detected using G92 (1:3000) or CUB7402 (1:2000) monoclonal antibodies 
and then anti-mouse IgG/HRP (1:5000, Sigma) and TMB substrate. 
 
Measurement of transglutaminase activity  
The microtiter plate assay based on the incorporation of 5-(biotinamido)pentylamine (Molecular Probes, Invitrogene) into 
immobilised N,N-dimethylated casein (DMC) was used as described before (Kiraly et al. 2009). The fibronectin bound TG2 
activity assay was performed as published earlier (Kiraly et al. 2006). Shortly, the wells were coated with 100 μl of 1 mg/ml 
human fibronectin in carbonate buffer pH 9.6 for 1 h at room temperature. After washing, the wells were coated with 3 μg 
recombinant enzyme in buffer A, then incubated with 200 ml of 1 mM 5-(biotinamido)-pentylamine substrate in 0.1 M Tris-HCl 
buffer, pH 8.5 containing 5 mM CaCl2, 10 mM DTT. Amine incorporation was detected as in the conventional method. 
 
 
Results and discussion 
 
1. The reference sequence of wild type transglutaminase 2 
TG2 was first cloned in the laboratory of Peter Davies (Gentile et al. 1991). The reference TGM2 sequence in the Ensemble 
database (obtained after the completion of the genome project) is shown in Fig. 1a. Comparing the two, five non-synonymous 
differences are seen in the former and we realized that these variants are also listed in the UniProt database as sequence conflicts 
(Fig. 1b). The TGM2 cDNA construct used in our and many other laboratories is the firstly cloned cDNA originating from the 
Davies’ lab. After sequencing this cDNA (ABI PRISM) several times we found that it has the reference nucleotide sequence and 
not the conflicting one at four of the five disputed sites. The lower reliability of the classical sequencing technique used 20 years 
ago probably explains this discrepancy. Until this time there has been no reported genome sequence which contains any of the 
four non-synonymous alleles. There is one exception, however, it is Gly224 in the Gentile sequence as opposed to Val224 in the 
reference sequence. We have validated this variant by re-sequencing the Gentile cDNA several times and suspect that it is either a 
mutation in the genome of the person from where TG2 was originally cloned or a mutation generated during the cloning 
procedures. It should be clarified whether this difference has any functional significance since to our knowledge many of the 
published transfection, recombinant and structural studies in the last two decades have been carried out using this cDNA, which is 
not the most frequent variant of the enzyme. Silent changes may in turn alter the expression level of TG2. Therefore, we have also 
analyzed the validity of such variants of the Gentile cDNA and found only one silent nucleotide change (in the triplet coding for 
Leu291) which could be confirmed as different from the reference sequence (Fig. 1b). 
Due to the above mentioned differences we also have analyzed the available data (allele frequency of the single 
nucleotide changes) of the 1000 Genome database and Complete Genomics high coverage sequencing diversity panel results. 
These databases provide the newest, high fidelity sequence data. The comparison of these sequences confirms that the TGM2 
reference sequence, which can be found in the Ensemble database, is indeed by far the most common haplotype of the TGM2 
gene (see also data and discussion in the next and the 4th section). 
 
2. SNPs in the TGM2 gene 
At the time of writing the present article 365 SNPs have been reported in the databases for the 38 kb TGM2 gene. Of these 34 
SNPs are in the coding region, 18 are non-synonymous mutations (Table 1), 14 are synonymous and 2 would lead to frameshift 
and shorter protein. Only 8 missense SNPs have frequency data (2 others were found only in single genome): they occur in low 
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frequency in the population and all are heterozygous. The analysis of the 1000 Genomes database also confirms that the frequency 
of the non-synonymous changes in TGM2 is very low while it has synonymous SNPs with average frequency. 
It should be noted that the databases contain some controversial data. Some of the SNPs are listed differently in the 
databases and sometimes the frequency value of the same SNP varies from one database to the other. Some SNPs have 
identification number but their heterozygosity value is 0.000 and in the population genetic data there is no chromosome which 
contains the particular variant (e.g. in the NCBI database rs146621816, rs139974885).  
In the literature three missense mutations (Asn333Ser, Met330Arg and Ile331Asn) were described in patients of Maturity 
Onset Diabetes of the Young (MODY) or early-onset type 2 diabetes. These variants have impaired transglutaminase activity 
(TGase) suggesting that enzymatic activity of TG2 can play a role in disorders of glucose metabolism (Porzio et al. 2007; 
Bernassola et al. 2002). However, there is no direct evidence that these mutations contribute to the development of diabetes in 
these patients. In a British population eight non-coding SNPs across the TGM2 gene were genotyped and it was suggested that the 
detected variants were associated with schizophrenia and TGM2 may have a role in the development of this mental disease 
(Bradford et al. 2009). In another study a major fraction of human protein coding genes was examined
 
in breast and colorectal 
cancer (Sjöblom et al. 2006) to determine the spectrum and extent of somatic mutations; TGM2 was one of the genes with a 
somatic mutation (Gly660Val).  
 
3. Functional consequence of TG2 mutations 
Based on the data obtained from the databases between 2009 and 2010 eleven variants or mutants were produced in our laboratory 
by site directed mutagenesis. The studied variants were selected on the basis of some predictions for the potential effect of the 
amino acid change by comparing TGM2 to other transglutaminase family members and expecting that some SNPs in regions 
which are well conserved in the family may lead to serious functional defects while others, for example in the N terminal part, 
could cause just small deviances from the wild type protein. We predicted that SNPs close to the Ca
2+
-binding sites can also cause 
serious functional defects. 
After protein expression and one step Ni-NTA affinity purification the yield and purity of the variants were determined 
(Fig. 2). Although each variant could be expressed in a bacterial system, the yield and purity of the protein preparations were 
different. The Gly660Val mutant and FS153-169 double frame shift variants show lower purity and yield. In the case of the 
FS153-169 variant this is not surprising because in our previous work, when this region was modified by mutations, the stability 
and purity of the expressed proteins were also less compared to the wild type enzyme and other mutants (Kiraly et al. 2009). This 
region of TG2 could be responsible for the stabilization of the protein or its proper folding.  
Before studying the functional properties of the TG2 variants three monoclonal antibodies were used to compare their 
folding and binding properties on a microtiter plate (Fig. 3a). The G92 antibody recognizes the N-terminal part of TG2 (Trejo-
Skalli et al. 1995), the CUB7402 (Epitope: aa447-478) and TG100 (Epitope: aa447-538) reacts with the catalytic core domain of 
TG2. In the case of G92 and CUB7402 antibodies we could not see significant decrease in their binding to the mutant TG2. For 
the TG100 antibody the Arg436Thr and Pro536Ser variants showed slight, while the Gly660Val mutant and FS153-169 variant 
slight but significant decrease in the antibody binding. The structural change in the molecules may alter the antibody binding 
region or can decrease the stability of the variants.  
It is known that TG2 plays a role in coeliac disease where it is the main antigen. The coeliac antibody binding of the 
mutants was also tested by ELISA (Fig. 3b). The Arg214His and Pro536Ser variants show slight while the Gly660Val and FS153-
169 ones significant decrease in antibody binding. The lowest antibody binding was found in the case of the FS153-169 variant. 
There is a sequence overlap between the FS153-169 variant and the S4 Ca
2+
-binding site mutants produced in our previous work 
(Kiraly et al. 2009) where we also observed significant decrease in coeliac antibody binding. The present observation confirms 
that this region contains an important anchor point for the autoantibodies to bind TG2. 
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Since TG2 has a significant role in scaffolding processes at the extracellular side of the cells and its interaction with 
fibronectin has a crucial role in this function, the fibronectin binding property of the variants was also tested by an ELISA method 
(Fig. 4). The variants bound fibronectin similarly to the un-modified enzyme, except the Asp389Asn and FS153-169 variants 
which exhibited decreased but not totally lost binding. 
Finally, we measured transglutaminase activity of the variants in either their free or fibronectin bound form (Fig. 5). The 
Arg76His, Pro78Gln, Pro78Arg variants showed activity comparable to the un-modified enzyme. The Arg214His and FS153-169 
variants lost their transglutaminase activity in both assays. Asp389Asn, Arg436Thr and, Gly660Val variants had very low 
transglutaminase activity (under 10% compared to wild type) using the conventional microtiter plate method but they had 
significantly higher transglutaminase activity when the enzyme was bound to fibronectin. Actually, in case of the other variants 
also higher transamidase activity was observed when they were bound to fibronectin. This suggests that fibronectin binding may 
improve stability of the active conformation of TG2 variants.  
The results confirmed our functional prediction since the functionally defective variants have amino acid change in well 
conserved regions or close to the Ca
2+
-binding sites of TG2. Since most TG2 variants with non-synonymous changes in exon 
sequences result in defective proteins it is likely that their appearance in affected individuals may have pathologic consequences. 
They may disturb cellular and tissue functions when are manifested in both TGM2 alleles. No cases like that have been described 
so far. The pathologies observed in TG2 knockout mice, e.g. diabetes (Bernassola et al. 2002) and autoimmunity (Szondy et al. 
2003), may give a clue to what to expect in such genetic cases if ever occurred. Somatic mutations may also lead to TG2 
deficiency in cellular lineages or tumors contributing to tissue and disease specific malfunctions. Heterozygosity may also 
contribute to the development of complex diseases for example the missense mutations to the onset of MODY. Even at the present 
stage of genomic technologies it is a challenging task to prove association of rare frequency mutations with diseases; large 
cohorts, in the range of tens of thousands participants are needed to assess their contribution to pathologic phenotypes. However, 
recent developments in fast and precise DNA sequencing methods and the personal medicine approaches will open new 
possibilities to clarify the role and significance of rare SNPs, including the TG2 variants reported here, in various human 
pathologies. 
 
4. Comparison of the frequency of genetic variations in genes of the transglutaminase family 
In the Ensemble and 1000 Genomes database more than 100 single nucleotide changes are reported for FXIIIA and TGM1 and 
most of these are also listed as rare mutations in The Human Gene Mutation Database (http://www.hgmd.org) having causative 
roles in severe diseases such as FXIIIa deficiency with bleeding disorders (F13A1 mutants) and lamellar ichtyosis (TGM1). In the 
transglutaminase family F13A1, TGM3 and TGM6 have some SNPs (3-4) with high frequency occurrence (over 10 %) in the 
population while TGM2 and TGM1 have very low polymorphism. Regarding common variants the significance of Val34Leu 
polymorphism of Factor XIIIa have been assessed and was found to provide protection against myocardial infarction (Muszbek et 
al. 2010). The enzyme activity of the Val34Leu variant does not change but its thrombin activation is quicker than that of the most 
frequent sequence variant (Kohler at al. 1998; Var et al. 2009). Another frequent variant of Factor XIIIa is Pro564Leu (Anwar et 
al. 1999; Saha et al. 2000) with higher enzymatic activity but no physiologic or pathologic association. The numbers of variants of 
other transglutaminases in the databases are fewer than 40. Among them there are two interesting mutations in TGM5 which show 
association with the Acral Peeling Skin Syndrome (Gly113Cys, Cassidy et al. 2005; Trp255Arg, Lys445Asn, Kharfi et al. 2009). 
In order to compare the diversity in the coding sequences of the transglutaminase family genes we used the Complete 
Genomics diversity panel high coverage sequence data (Table 3). We counted the number of the observed diverse loci in each 
reference gene transcript and normalised the results based on the length of the proteins. We have also counted the number of 
individuals out of 46 examined genomes who are homo- or heterozygous on the given locus. The data show clearly that among the 
examined gene transcripts the TGM2 NM_198951 transcript has the lowest missense number per 100 amino acids, while the 
compatible (silent or synonymous) mutation rate of this transcript is at average. This proves that the TGM2 protein is under a 
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great purifying selective evolutionary pressure, which eliminates most of the missense mutations from the population. The reason 
for this strong evolutionary constraint is most likely the multiple, important functions of the protein in various cell compartments 
and outside of cells (Fesus and Piacentini 2002). It is also worth to note, however that both the TGM2 and the EPB42 genes, 
which have the lowest mutation rate (Table 3), have two annotated transcript and protein form. This would cause increased 
selectional pressure on different parts of the proteins and thus can explain partly the lower than average mutational rate. 
 
Conclusions 
 
Analysis of the available genomic databases clearly show that the protein coding sequence of human transglutaminase 2 has very 
low polymorphism in the population and it has the lowest variability when compared to other members of the human 
transglutaminase family. According to functional studies of the rare protein variants, which so far have been found encoded only 
as heterozygous forms in genomes, the amino acid changes lead to defective proteins. This raises the possibility that they 
contribute to the development of pathologic conditions that will be very difficult to find considering their very low frequency of 
occurrence. Based on these conclusions there is another important issue to address: how it is possible that while there is such a 
strong evolutionary pressure on human TGM2, the homozygous deletion of the mouse TGM2 does not result in life threatening 
phenotypes and these mice are fertile. Obviously, this and similar questions will generate exciting studies in the future resulting in 
important novel findings in human physiology and pathology. 
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Figure legends: 
 
Fig. 1 Protein sequence of TG2 based on the reference sequence (A) and its comparison with the published sequences (B). The 
TGM2 cDNA that we use in our laboratory has only one amino acid difference compared to the reference gene. However, the 
origin of our TG2 cDNA was the vector which was cloned and constructed by Gentile et al. We sequenced the Kojima 
laboratory’s (RIKEN Advanced Science Institute, Japan) TG2 construct and its sequence was the same as our clone (the origin of 
this clone is also Gentile). The shaded rows in the table show the non-synonymous nucleotide changes which result amino acids 
changes. 
 
Fig. 2 Purity and immunoreactivity of TG2 variants. (A) 4 μg protein sample / lane was visualised with Coomassie BB staining 
after 10% SDS-PAGE and (B) immunoblot of 0.5 μg protein sample / lane. Data are representative of two independent 
experiments. Control: un-modified recombinant TG2. 
 
Fig. 3 Monoclonal and coeliac antibody binding of TG2 variants. (A) The applied monoclonal antibodies recognize the TG2 
variants. (B) Patient 1 and 4 are untreated coeliac patients, control is a healthy donor. Dilution of the sera is 1:150. Binding to the 
un-modified TG2 (control) is 100%. Data are presented as means with ± standard deviations from two separate experiments 
performed in duplicate. 
 
Fig. 4 Fibronectin binding property of the TG2 variants. The fibronectin binding was detected using two different monoclonal 
antibodies. Binding of the un-modified TG2 (control) is 100%. Data are presented as means with ± standard deviations from two 
separate experiments performed in duplicate. 
 
Fig. 5 Transglutaminase activity of liquid phase and fibronectin bound TG2 variants. Transglutaminase activity is shown as a 
percentage of activity of the un-modified (control) TG2 (Specific activity of liquid phase un-modified TG2: 6.5 ΔAbs405/min/mg 
protein). Data are presented as means with ± standard deviations from two separate experiments performed in triplicate. 
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A 
 
  1
MAEELVLERC DLELETNGRD HHTADLCREK LVVRRGQPFW LTLHFEGRNY
50 
 51
EASVDSLTFS VVTGPAPSQE AGTKARFPLR DAVEEGDWTA TVVDQQDCTL
100
 
101
SLQLTTPANA PIGLYRLSLE ASTGYQGSSF VLGHFILLFN AWCPADAVYL
150
 
151
DSEEERQEYV LTQQGFIYQG SAKFIKNIPW NFGQFEDGIL DICLILLDVN
200
 
201
PKFLKNAGRD CSRRSSPVYV GRVVSGMVNC NDDQGVLLGR WDNNYGDGVS
250
 
251
PMSWIGSVDI LRRWKNHGCQ RVKYGQCWVF AAVACTVLRC LGIPTRVVTN
300
 
301
YNSAHDQNSN LLIEYFRNEF GEIQGDKSEM IWNFHCWVES WMTRPDLQPG
350
 
351
YEGWQALDPT PQEKSEGTYC CGPVPVRAIK EGDLSTKYDA PFVFAEVNAD
400
 
401
VVDWIQQDDG SVHKSINRSL IVGLKISTKS VGRDEREDIT HTYKYPEGSS
450
 
451
EEREAFTRAN HLNKLAEKEE TGMAMRIRVG QSMNMGSDFD VFAHITNNTA
500
 
501
EEYVCRLLLC ARTVSYNGIL GPECGTKYLL NLNLEPFSEK SVPLCILYEK
550
 
551
YRDCLTESNL IKVRALLVEP VINSYLLAER DLYLENPEIK IRILGEPKQK
600
 
601
RKLVAEVSLQ NPLPVALEGC TFTVEGAGLT EEQKTVEIPD PVEAGEEVKV
650
 
651
RMDLLPLHMG LHKLVVNFES DKLKAVKGFR NVIIGPA
687 
 
B 
 
AA 
position 
Reference gene 
(Ensemble) 
PDB database First published (Gentile 
et al. 1991) 
Gentile clone sequenced  
in Debrecen, Hungary 
n
o
n
-
sy
n
o
n
ym
o
u
s 51 Glu (gag) Gln Gln (cag) Glu (gag) 
186 Glu (gaa) Gln Gln (caa) Glu (gaa) 
224 Val (gtg) Gly Gly (ggt) Gly (ggt) 
533 Asn (aac) Thr Thr (acc) Asn (aac) 
655 Leu (ctg) Val Val (gtg) Leu (ctg) 
      
sy
n
o
n
ym
o
u
s 213 Arg (cgc) Arg Arg (cgg) Arg (cgc) 
291 Leu (ctg) Leu Leu (cta) Leu (cta) 
367 Gly (ggg) Gly Gly (gga) Gly (ggg) 
532 Leu (ctc) Leu Leu (cta) Leu (ctc) 
654 Leu (ctg) Leu Leu (ctc) Leu (ctg) 
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